Metabonomics - Articles and news items

Pills Powder

Evolution of drug metabolism and pharmacokinetics in drug discovery and development

Drug Discovery, Issue 3 2012 / 10 July 2012 / Dr. Dermot McGinnity, Innovative Medicines, AstraZeneca R&D

Drug Metabolism and Pharmacokinetics (DMPK) is a scientific discipline once primarily associated with safety evaluation in drug development that has, in the last two decades, become a core discipline within drug discovery, development and even post-marketing. Approximately 20 years ago, sub-optimal DMPK properties were recognised as a contributor to the failure of potential new therapies in early clinical trials and this precipitated the realignment of DMPK within discovery to assist in selecting optimal drug candidates to enter clinical trials. In addition to adequate potency against the target protein and an acceptable safety profile, a balance of optimised PK parameters and minimised drug-drug interaction (DDI) potential maximises the chance of a candidate drug becoming a successful therapy…

Evaluating drug safety

Issue 1 2005, Past issues / 7 March 2005 / Donald G. Robertson, Metabonomics Evaluation Group, Departments of Worldwide Safety Sciences and Michael D. Reily, Discovery Technologies, Pfizer Global Research and Development

Metabonomics has been defined as the “the quantitative measurement of the time-related multi-parametric metabolic response of living systems to pathophysiological stimuli or genetic modification”1. In simple terms it is a powerful tool for assessing the metabolic component of systemic response.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...